Skip to main content

Nivolumab / relatlimab Side Effects

Medically reviewed by Drugs.com. Last updated on Feb 4, 2024.

Applies to nivolumab / relatlimab: intravenous solution.

Serious side effects

Along with its needed effects, nivolumab/relatlimab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking nivolumab / relatlimab:

More common

Less common

Rare

Other side effects

Some side effects of nivolumab / relatlimab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to nivolumab / relatlimab: intravenous solution.

General

The most frequent (greater than 1%) serious adverse events reported in clinical trials were adrenal insufficiency, anemia, colitis, pneumonia, acute myocardial infarction, back pain, diarrhea, myocarditis, and pneumonitis. The most common (greater than 20%) adverse reactions were musculoskeletal pain, fatigue, rash, pruritus, and diarrhea.[Ref]

Cardiovascular

Frequency not reported: Myocarditis[Ref]

Dermatologic

Very common (10% or more): Rash (28%), pruritus (25%)

Frequency not reported: Vitiligo[Ref]

Endocrine

Very common (10% or more): Hypothyroidism (17%)

Frequency not reported: Adrenal insufficiency

Gastrointestinal

Very common (10% or more): Diarrhea (24%), nausea (17%)[Ref]

Hematologic

Very common (10% or more): Decreased hemoglobin (37%), decreased lymphocytes (32%)[Ref]

Hepatic

Very common (10% or more): Increased AST (30%), increased ALT (26%)

Frequency not reported: Hepatitis[Ref]

Metabolic

Very common (10% or more): Decreased appetite (15%), increased alkaline phosphatase (19%)[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (45%)[Ref]

Nervous system

Very common (10% or more): Headache (18%)[Ref]

Other

Very common (10% or more): Fatigue (39%), decreased sodium (24%)[Ref]

Renal

Very common (10% or more): Increased creatinine (19%)[Ref]

Respiratory

Very common (10% or more): Cough (15%)

Common (1% to 10%): Pneumonitis[Ref]

References

1. Product Information. Opdualag (nivolumab-relatlimab). Bristol-Myers Squibb Australia Pty Ltd. 2023;2.

2. Product Information. Opdualag (nivolumab-relatlimab). Bristol-Myers Squibb. 2022.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.